Takeda Pharmaceutical Co Ltd ADR

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$1,106,685,000
$1,053,400,000
$1,144,124,000
$1,176,038,000
Gross Profit
722,010,000
671,300,000
727,250,000
781,727,000
EBITDA
439,424,000
181,269,000
193,007,000
380,278,000
EBIT
257,788,000
-8,500,000
6,052,000
187,826,000
Net Income
124,243,000
-103,200,000
23,789,000
92,046,000
Net Change In Cash
1,106,685,000
1,053,400,000
1,144,124,000
1,176,038,000
Free Cash Flow
140,355,000
173,366,000
338,668,000
209,526,000
Cash
350,008,000
385,113,000
494,126,000
859,015,000
Basic Shares
3,176,352
3,163,218
3,170,000
3,220,064

Annual Financials

Values in thousands 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Revenue
$4,581,551,000
$4,263,762,000
$4,027,478,000
$3,569,006,000
Gross Profit
3,001,334,000
2,832,257,000
2,783,406,000
2,462,160,000
EBITDA
1,210,512,000
874,601,000
1,184,514,000
1,183,213,000
EBIT
449,116,000
146,599,000
520,114,000
600,062,000
Net Income
107,928,000
144,067,000
317,017,000
230,059,000
Net Change In Cash
4,581,551,000
4,263,762,000
4,027,478,000
3,569,006,000
Free Cash Flow
856,387,000
235,614,000
343,467,000
937,068,000
Cash
385,113,000
457,800,000
533,530,000
849,695,000
Basic Shares
3,210,710
3,160,686
3,139,744
3,154,338

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
$151
2025-03-31
-$0.22
2024-12-31
$0.04